Fine Needle Tissue Acquisition
Otherdiagnostic
Other names: FNTA
NCT Number: NCT04032951
To determine the yield of tissue biopsy specimen and the diagnostic accuracy of tissue acquisition using a newly developed 22 gauge needle in patients with solid lesions throughout the GI tract.
Looking for future studies?
Notify Me10 year–80 year
All sexes
Interventional
Not applicable
ISMETT, Palermo, Italy
The use of 22 gauge needle to gather tissue samples under EUS guidance has not been associated with an increased risk, and no major complications have been described so far both for the 22 gauge Procore needle and for standard 22 gauge.20, 21 Potential benefits of this new needle are the possibility of increasing the chance of retrieving tissue specimens for histological examination, with the possibility of increasing the diagnostic accuracy of the procedure saving the need and the cost deriving from on-site cytopathology examination. This may reduce the need to repeat EUS procedures or other more invasive sampling procedures, including surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
diagnostic
Other names: FNTA
Time frame: intraoperative
diagnostic accuracy
Time frame: perioperative
Catholic University of the Sacred Heart
Other
Evaluation of a Newly Designed 22 Gauge Needle for EUS Guided Tissue Acquisition of Samples for Histologic Examination in Patients With Solid Lesions: A Prospective Two Centers Study
Acronym: EUSFNTA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02307253
Abdominal Neoplasms, Neoplasms
Indianapolis, Indiana, United States
View Trial DetailsNCT03002909
Abdominal Neoplasms, Neoplasms
Asyut, Egypt
View Trial DetailsNCT02653469
Abdominal Neoplasms, Female Urogenital Diseases
Seoul, South Korea
View Trial DetailsNCT00186953
Abdominal Neoplasms, Neoplasms
Memphis, Tennessee, United States
View Trial Details